Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Atrial cardiomyopathy in patients with ischaemic stroke: a cross-sectional and prospective cohort study-the COAST study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sex-Differences in Oral Anticoagulant-Related Intracerebral Hemorrhage

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Stroke admissions and revascularization treatments in Denmark during COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Melinda B Roaldsen
  • Haakon Lindekleiv
  • Agnethe Eltoft
  • Mirza Jusufovic
  • Mary-Helen Søyland
  • Jesper Petersson
  • Bent Indredavik
  • Arnstein Tveiten
  • Jukka Putaala
  • Hanne Christensen
  • Janika Kõrv
  • Dalius Jatužis
  • Stefan T Engelter
  • Gian Marco De Marchis
  • Tom Wilsgaard
  • David J Werring
  • Thompson Robinson
  • Ellisiv B Mathiesen
  • Eivind Berge
View graph of relations

BACKGROUND: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced imaging can benefit from intravenous thrombolysis. It is not known whether patients who do not fulfil such imaging criteria might benefit from treatment, but studies indicate that treatment based on non-contrast CT criteria may be safe. Tenecteplase has shown promising results in patients with acute ischemic stroke. The aim of the Tenecteplase in Wake-up Ischemic Stroke Trial (TWIST) is to compare the effect of thrombolytic treatment with tenecteplase and standard care versus standard care alone in patients with wake-up ischemic stroke selected by non-contrast CT.

METHODS/DESIGN: TWIST is an international, investigator-initiated, multi-centre, prospective, randomized-controlled, open-label, blinded end-point trial of tenecteplase (n = 300) versus standard care (n = 300) in patients who wake up with an acute ischemic stroke and can be treated within 4.5 h upon awakening. Seventy-seven centres in 10 countries (Denmark, Estonia, Finland, Latvia, Lithuania, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom) participate. The primary outcome is the modified Rankin Scale on the ordinal scale (0-6) at three months.

DISCUSSION: TWIST aims to determine the effect and safety of thrombolytic treatment with tenecteplase in patients with wake-up ischemic stroke selected by non-contrast CT.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03181360. EudraCT Number 2014-000096-80.

Original languageEnglish
JournalInternational journal of stroke : official journal of the International Stroke Society
Volume16
Issue number8
Pages (from-to)990-994
Number of pages5
ISSN1747-4930
DOIs
Publication statusPublished - Oct 2021

    Research areas

  • Brain Ischemia/drug therapy, Fibrinolytic Agents/therapeutic use, Humans, Ischemic Stroke/drug therapy, Prospective Studies, Randomized Controlled Trials as Topic, Tenecteplase/therapeutic use, Tissue Plasminogen Activator/therapeutic use, Treatment Outcome

ID: 74892807